(Total Views: 125)
Posted On: 08/21/2018 10:00:02 AM
Post# of 617763
Lixte Biotechnology Holdings, Inc. (LIXT: OTCQB) | Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
(0)
(0)
